XML 82 R75.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Information - Schedule of Segment Reporting Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Segment Reporting Information [Line Items]          
Revenues $ 30,564 $ 25,488 $ 79,393 $ 77,885  
Cost of revenues 1,628 958 3,673 2,707  
Gross profit 28,936 24,530 75,720 75,178  
Operating expenses excluding cost of revenues:          
Selling and marketing 15,328 13,699 41,363 40,655  
Research and development 2,363 2,775 8,883 8,312  
General and administrative 4,319 3,823 14,103 10,645  
Loss on disposal of assets, net 1   2 68  
Total operating expenses excluding cost of revenues 22,011 20,297 64,351 59,680  
Income from operations 6,925 4,233 11,369 15,498  
Other income (expense), net 727 (75) 689 (25)  
Change in fair value of warrant liability (23) (228) 2,444 6,973  
Income tax expense (1,693) (1,074) (3,256) (5,117)  
Net income (loss) 5,936 2,856 11,246 17,329  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 1,147 237 2,560 264  
Total assets 159,384   159,384   $ 125,406
Purchase of property and equipment     1,046 2,380  
Cost of revenue          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 38   85    
Selling and marketing          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 24   53    
General and administrative          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 1,085 237 2,422 264  
Gyre Pharmaceuticals          
Segment Reporting Information [Line Items]          
Revenues 30,564 25,488 79,393 77,885  
Cost of revenues 1,628 958 3,673 2,707  
Gross profit 28,936 24,530 75,720 75,178  
Operating expenses excluding cost of revenues:          
Selling and marketing 15,328 13,699 41,363 40,655  
Research and development 2,146 2,553 8,512 7,639  
General and administrative 2,595 2,225 9,008 7,031  
Loss on disposal of assets, net 1   2 68  
Total operating expenses excluding cost of revenues 20,070 18,477 58,885 55,393  
Income from operations 8,866 6,053 16,835 19,785  
Other income (expense), net 510 (4) 335 111  
Income tax expense (1,691) (1,074) (3,254) (5,117)  
Net income (loss) 7,685 4,975 13,916 14,779  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 339   766    
Total assets 130,030   130,030   114,248
Purchase of property and equipment     1,046 2,366  
Gyre Pharmaceuticals | Cost of revenue          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 38   85    
Gyre Pharmaceuticals | Selling and marketing          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 24   53    
Gyre Pharmaceuticals | General and administrative          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 277   628    
Gyre          
Operating expenses excluding cost of revenues:          
Research and development 217 222 371 673  
General and administrative 1,713 1,593 5,079 3,608  
Total operating expenses excluding cost of revenues 1,930 1,815 5,450 4,281  
Income from operations (1,930) (1,815) (5,450) (4,281)  
Other income (expense), net 217 (71) 354 (136)  
Change in fair value of warrant liability (23) (228) 2,444 6,973  
Income tax expense (2)   (2)    
Net income (loss) (1,738) (2,114) (2,654) 2,556  
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 808 237 1,794 264  
Total assets 28,997   28,997   10,790
Purchase of property and equipment       14  
Gyre | General and administrative          
Supplemental disclosure of stock-based compensation expense:          
Stock-based compensation 808 237 1,794 264  
Other          
Operating expenses excluding cost of revenues:          
General and administrative 11 5 16 6  
Total operating expenses excluding cost of revenues 11 5 16 6  
Income from operations (11) (5) (16) (6)  
Net income (loss) (11) $ (5) (16) $ (6)  
Supplemental disclosure of stock-based compensation expense:          
Total assets $ 357   $ 357   $ 368